Company Overview and News

1
FCSC / Fibrocell Science Inc. null

2018-09-07 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C<@,"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S(P M-34O3R [email protected],C
FCSC

1
FCSC / Fibrocell Science Inc. null

2018-09-07 sec.gov
Document Fibrocell Science, Inc.
FCSC

34
Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized Scleroderma

2018-09-05 globenewswire - 1
EXTON, Pa., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to FCX-013, the Company’s clinical stage candidate for the treatment of moderate to severe localized scleroderma—a chronic, debilitating genetic skin disorder with no FDA approved therapies.
XON FCSC

1
FCSC / Fibrocell Science Inc. 8-K (Current Report)

2018-09-05 sec.gov
Document UNITED STATES
FCSC

33
Fibrocell to Present at 20th Annual Rodman & Renshaw Global Investment Conference

2018-08-29 globenewswire
EXTON, Pa., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski, President and Chief Executive Officer, will present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H. C. Wainwright & Co., LLC.
XON FCSC

33
Intrexon Reports Preliminary Earnings and Revenues for Q2

2018-08-11 zacks
The company expects to incur basic loss of 17 cents per share (excluding non cash expenses). The Zacks Consensus Estimate stands at a loss of 23 cents.
ZIOP GJV XON NWS NWSA FCSC

34
Fibrocell Science, Inc. (FCSC) CEO John Maslowski on Q2 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha - 1
Good morning. My name is Sarah, and I will be your conference operator today. At this time, I would like to welcome everyone to Fibrocell's Second Quarter 2018 Financial Results and Operational Highlights Conference Call.
XON FCSC

1
FCSC / Fibrocell Science Inc. 8-K (Current Report)

2018-08-09 sec.gov
Document UNITED STATES
FCSC

33
What's in Store for Intrexon (XON) This Earnings Season?

2018-07-31 zacks
Intrexon Corporation (XON - Free Report) is expected to report second-quarter 2018 results on Aug 8, after the market closes.
WCN AMKR XON PCRX FCSC UTX ENL ENDP

3
Fibrocell Science: An Underappreciated Gene Therapy Play

2018-07-27 seekingalpha - 1
There are clear risks in terms of continued dilution, but we believe these risks are outweighed by the positive data presented from Fibrocell's lead gene therapy program, FCX-007.
FCSC KRYS ABEO ABEOW

1
FCSC / Fibrocell Science Inc. S-1

2018-07-27 sec.gov
Document As filed with the Securities and Exchange Commission on July 27, 2018
FCSC

12
FCSC / Fibrocell Science Inc. 8-K (Current Report)

2018-07-05 sec.gov - 11
Document UNITED STATES
FCSC

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

17h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

17h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

19h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 315721209